| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to drugs, and concerns an application of an LXR agonist for preparing a drug effective for treatment and/or prevention of type I diabetes and a method of increasing primary pancreatic islet viability ex vivo wherein said pancreatic islets contact with the LXR agonist. ^ EFFECT: extended range of products for type I diabetes treatment. ^ 13 cl, 8 dwg, 8 ex |
